Dimensional Fund Advisors LP Takes $217,000 Position in Kezar Life Sciences, Inc. (NASDAQ:KZR)

Dimensional Fund Advisors LP bought a new position in Kezar Life Sciences, Inc. (NASDAQ:KZR) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 32,310 shares of the company’s stock, valued at approximately $217,000. Dimensional Fund Advisors LP owned about 0.44% of Kezar Life Sciences at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Peapod Lane Capital LLC purchased a new position in Kezar Life Sciences during the 4th quarter worth approximately $833,000. BML Capital Management LLC purchased a new stake in Kezar Life Sciences in the fourth quarter valued at $327,000. Finally, JPMorgan Chase & Co. grew its holdings in Kezar Life Sciences by 613.8% during the fourth quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock worth $80,000 after acquiring an additional 10,219 shares during the period. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Analysts Set New Price Targets

Separately, William Blair restated an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th.

Kezar Life Sciences Stock Up 0.2%

Shares of KZR opened at $4.07 on Friday. Kezar Life Sciences, Inc. has a one year low of $3.62 and a one year high of $9.18. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65. The stock has a 50 day moving average price of $4.64 and a 200 day moving average price of $5.94. The stock has a market capitalization of $29.74 million, a price-to-earnings ratio of -0.31 and a beta of 0.61.

Kezar Life Sciences (NASDAQ:KZR) last issued its earnings results on Tuesday, May 13th. The company reported ($2.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.56) by $0.29. Equities research analysts forecast that Kezar Life Sciences, Inc. will post -4.39 earnings per share for the current fiscal year.

Kezar Life Sciences Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.